These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 7686944)

  • 21. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG
    Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evaluation of diagnostic efficiency of the recombinant protein modeling immunodominant epitope V3 of envelope gp120 for immunoenzyme detection for HIV-1 infection antibodies].
    Riabinina SA; Baranova EN; Sharipova IN; Susekina MI; Puzyrev VF; Obriadina AP; Burkov AN; Ulanova TI
    Mol Gen Mikrobiol Virusol; 2007; (3):33-6. PubMed ID: 17886471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope.
    Garrity RR; Rimmelzwaan G; Minassian A; Tsai WP; Lin G; de Jong JJ; Goudsmit J; Nara PL
    J Immunol; 1997 Jul; 159(1):279-89. PubMed ID: 9200464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
    Kang CY; Hariharan K; Nara PL; Sodroski J; Moore JP
    J Virol; 1994 Sep; 68(9):5854-62. PubMed ID: 7520095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation.
    Tian H; Xiao Y; Qin L; Chen YH
    Immunobiology; 2001 Dec; 204(4):434-41. PubMed ID: 11776398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates.
    Pinter A; Honnen WJ; Racho ME; Tilley SA
    AIDS Res Hum Retroviruses; 1993 Oct; 9(10):985-96. PubMed ID: 7506556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon induction by HIV glycoprotein 120: role of the V3 loop.
    Ankel H; Capobianchi MR; Castilletti C; Dianzani F
    Virology; 1994 Nov; 205(1):34-43. PubMed ID: 7526537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interactions among HIV gp120, CD4, and CXCR4: dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH- and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies.
    Mondor I; Moulard M; Ugolini S; Klasse PJ; Hoxie J; Amara A; Delaunay T; Wyatt R; Sodroski J; Sattentau QJ
    Virology; 1998 Sep; 248(2):394-405. PubMed ID: 9721247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization.
    Back NK; Smit L; De Jong JJ; Keulen W; Schutten M; Goudsmit J; Tersmette M
    Virology; 1994 Mar; 199(2):431-8. PubMed ID: 8122371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.
    Gorny MK; Xu JY; Karwowska S; Buchbinder A; Zolla-Pazner S
    J Immunol; 1993 Jan; 150(2):635-43. PubMed ID: 7678279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoclonal anti-idiotypic antibody mimicking the principal neutralization site in HIV-1 GP120 induces HIV-1 neutralizing antibodies in rabbits.
    Fung MS; Sun CR; Liou RS; Gordon W; Chang NT; Chang TW; Sun NC
    J Immunol; 1990 Oct; 145(7):2199-206. PubMed ID: 2398276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of GP120 binding to CD4 and an assay that measures ability of sera to inhibit this binding.
    Schnittman SM; Lane HC; Roth J; Burrows A; Folks TM; Kehrl JH; Koenig S; Berman P; Fauci AS
    J Immunol; 1988 Dec; 141(12):4181-6. PubMed ID: 3264307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD4 epitope masking by gp120/anti-gp120 antibody complexes. A potential mechanism for CD4+ cell function down-regulation in AIDS patients.
    Amadori A; De Silvestro G; Zamarchi R; Veronese ML; Mazza MR; Schiavo G; Panozzo M; De Rossi A; Ometto L; Mous J
    J Immunol; 1992 May; 148(9):2709-16. PubMed ID: 1374095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of the cross-reactive anti-gp120 antibody population in human immunodeficiency virus-infected asymptomatic individuals.
    Hariharan K; Nara PL; Caralli VM; Norton FL; Haigwood N; Kang CY
    J Virol; 1993 Feb; 67(2):953-60. PubMed ID: 7678311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a synthetic peptide that mimics an HIV glycoprotein 120 envelope conformational determinant exposed following ligation of glycoprotein 120 by CD4.
    Weinberg J; Liao HX; Torres JV; Matthews TJ; Robinson J; Haynes BF
    AIDS Res Hum Retroviruses; 1997 May; 13(8):657-64. PubMed ID: 9168234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of antibody valency on interaction with cell-surface expressed HIV-1 and viral neutralization.
    Cavacini LA; Emes CL; Power J; Duval M; Posner MR
    J Immunol; 1994 Mar; 152(5):2538-45. PubMed ID: 7510748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers.
    Pincus SH; Messer KG; Nara PL; Blattner WA; Colclough G; Reitz M
    J Clin Invest; 1994 Jun; 93(6):2505-13. PubMed ID: 7515393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1.
    Armstrong SJ; McInerney TL; McLain L; Wahren B; Hinkula J; Levi M; Dimmock NJ
    J Gen Virol; 1996 Dec; 77 ( Pt 12)():2931-41. PubMed ID: 9000083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.
    Kang CY; Nara P; Chamat S; Caralli V; Ryskamp T; Haigwood N; Newman R; Köhler H
    Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6171-5. PubMed ID: 2068099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [An enzyme-linked immunosorbent assay determining anti-principal neutralizing determinant antibodies using synthetic peptides deduced from cDNA sequences of HIV-1 V3 loop domain].
    Ishimoto S; Fujimura Y; Yamanaka T; Shimoyama T; Nishida S; Matsuoka H; Nishikawa K; Yoshioka A; Narita N; Honda M
    Rinsho Ketsueki; 1995 Mar; 36(3):193-9. PubMed ID: 7540222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.